New Antimicrobials Celebrated as a 'Major Shift' in Treating Drug-Resistant Gonorrhoea

The first new treatments for gonorrhoea in many years are being hailed as a "major milestone" in the battle against superbug strains of the bacteria, according to scientists.

A Global Challenge

The sexually transmitted infection are increasing globally, with estimates suggesting in excess of 82 million new cases annually. Particularly high rates are observed in the African continent and countries within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary development in the context of growing infection rates, escalating drug resistance and the very limited available drugs presently on offer.”

Medical experts are particularly alarmed about the surge in antibiotic-resistant strains. The World Health Organization has designated it as a "critical concern". A tracking program showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Treatment Options Gain Authorization

Zoliflodacin, also known as Nuzolvence, was authorized by the American regulatory agency in mid-December for treating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Experts believe that focused deployment of this new drug will help hinder the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, also received approval in close succession. This treatment, which is also used to treat urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin emerged from a unique collaborative effort for drug creation. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to develop it.

“This approval marks a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Research Study Data and Global Access

Based on results published in a major medical journal, the new drug eradicated more than 90% of uncomplicated infections. This places it at an equal footing with the typical regimen, which uses an injection and a pill. The study involved nearly 1,000 patients from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the rights to register and commercialise the drug in numerous low-income and middle-income countries.

Medical professionals treating patients have expressed positive views. Access to a single-dose, oral treatment of this kind is seen as a "critical tool" for managing the epidemic. This is deemed crucial to lessen the impact of the disease for people and to stop the proliferation of highly drug-resistant gonorrhoea around the world.